KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 227 filers reported holding KITE PHARMA INC in Q2 2017. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $278,346,000 | +1884.5% | 1,548,000 | +1044.1% | 0.03% | +1600.0% |
| Q2 2017 | $14,026,000 | -78.9% | 135,298 | -84.0% | 0.00% | -75.0% |
| Q1 2017 | $66,510,000 | +64.2% | 847,373 | -6.2% | 0.01% | +60.0% |
| Q4 2016 | $40,516,000 | -42.5% | 903,573 | -28.4% | 0.01% | -44.4% |
| Q3 2016 | $70,505,000 | -39.1% | 1,262,173 | -45.5% | 0.01% | -43.8% |
| Q2 2016 | $115,796,000 | -7.0% | 2,315,928 | -14.6% | 0.02% | -5.9% |
| Q1 2016 | $124,491,000 | -43.0% | 2,711,628 | -23.5% | 0.02% | -41.4% |
| Q4 2015 | $218,419,000 | +23.7% | 3,544,628 | +11.7% | 0.03% | +16.0% |
| Q3 2015 | $176,639,000 | -10.9% | 3,172,403 | -2.4% | 0.02% | 0.0% |
| Q2 2015 | $198,274,000 | +21.6% | 3,252,003 | +15.1% | 0.02% | +19.0% |
| Q1 2015 | $163,000,000 | +43.6% | 2,825,942 | +43.6% | 0.02% | +40.0% |
| Q4 2014 | $113,500,000 | +301.6% | 1,968,094 | +98.4% | 0.02% | +275.0% |
| Q3 2014 | $28,265,000 | – | 991,755 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |